Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Egrifta SV | tesamorelin | Theratechnologies | N-22505 RX | 2011-11-29 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
egrifta sv | Biologic Licensing Application | 2024-12-12 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hiv-associated lipodystrophy syndrome | EFO_1001348 | D039682 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv | D006678 | — | O98.7 | 1 | — | — | 1 | 1 | 3 |
Retinal diseases | D012164 | — | H35.9 | — | — | — | 1 | — | 1 |
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
Lipodystrophy | D008060 | — | E88.1 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | — | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | — | — | 1 |
Wasting syndrome | D019282 | — | — | — | 1 | — | — | — | 1 |
Obstructive lung diseases | D008173 | — | — | — | 1 | — | — | — | 1 |
Cachexia | D002100 | — | R64 | — | 1 | — | — | — | 1 |
Muscular atrophy | D009133 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv seropositivity | D006679 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Tesamorelin |
INN | tesamorelin |
Description | Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.
|
Classification | Peptide |
Drug class | prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1237026 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | MQG94M5EEO (ChemIDplus, GSRS) |